Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations.

Trial Profile

Safety and Immunogenicity of Live Attenuated Herpes Zoster Vaccine in Patients Undergoing Living Donor Kidney Transplantations.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 May 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 May 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 26 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 16 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top